FCM
XGN icon

Farallon Capital Management’s Exagen XGN Stock Holding History

Farallon Capital Management’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-577,699
Closed -$14.7M – 117
2019
Q4 		$14.7M Buy
577,699
+214,363
+59% +$3.81M 0.1% 95
2019
Q3 		$5.63M Buy
+363,336
New +$5.87M 0.04% 88

Other funds holding XGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Farallon Capital Management's XGN Position: Q1 2020 in Review

Farallon Capital Management sold out of Exagen (XGN) in Q1 2020, closing a stake of 577,699 shares — an estimated $14.7M sold.

Farallon Capital Management first reported a position in XGN in Q3 2019 and held it in 2 quarters. The position peaked at $14.7M in Q4 2019. 32 funds tracked by Wall St. Rank hold XGN as of Q1 2020.

  • Farallon Capital Management reported no remaining Exagen position as of Q1 2020 after selling out during the quarter.
  • Farallon Capital Management sold 577,699 Exagen shares in Q1 2020, an estimated $14.7M.
  • Farallon Capital Management first reported a position in Exagen in Q3 2019 and held it in 2 quarters.
  • Farallon Capital Management's Exagen position peaked at $14.7M in Q4 2019.
  • 32 funds tracked by Wall St. Rank held Exagen as of Q1 2020.

Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.